Eva Pharmaceuticals is utilizing technology developed over a 10 year period in the field of radiation oncology and radiation bioterror research. The company's mission is to revolutionize the market for radio-protection, to be the premier provider of agents that prevent, mitigate or treat the deleterious effects of radiation. Until now, the field of agents that can mitigate the deleterious effects of radiation on human tissue has been, at best, relatively shallow. Through a technology partnership with the University of Rochester, Eva is ready to completely change the paradigm on such agents, with an impressive pipeline of drugs that are effective on all the major organ systems in the body
